



## Biktarvy<sup>®</sup> (BIC/FTC/TAF)

# Use in Continuous Renal Replacement Therapy

This document is in response to your request for information regarding Biktarvy<sup>®</sup> (bictegravir/emtricitabine/tenofovir alafenamide [BIC/FTC/TAF]) and its use in individuals on continuous renal replacement therapy.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

**The full indication, important safety information, and boxed warnings are available at: [www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi).**

---

## Product Labeling<sup>1</sup>

BIC/FTC/TAF is not recommended in individuals with severe renal impairment (estimated CrCl of 15 to <30 mL/min) or ESRD (estimated CrCl <15 mL/min) who are not receiving chronic HD. BIC/FTC/TAF is also not recommended in individuals with no antiretroviral treatment history and ESRD who are receiving chronic HD.

---

## Literature Search

A literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and March 19, 2026 using search terms that included Biktarvy, bictegravir, tenofovir alafenamide, emtricitabine, continuous renal replacement therapy, and other related search terms. No relevant citations were identified.

---

## References

1. Enclosed, Gilead Sciences Inc. BIKTARVY<sup>®</sup> (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. US Prescribing Information. Foster City, CA.

---

## Abbreviations

BIC=bictegravir  
ESRD=end stage renal disease

FTC=emtricitabine  
HD=hemodialysis

TAF=tenofovir alafenamide

---

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Biktarvy US Prescribing Information available at:

[www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi).

## Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 [www.askgileadmedical.com](http://www.askgileadmedical.com)

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or  
🌐 <https://www.gilead.com/utility/contact/report-an-adverse-event>

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [gilead.privacy@gilead.com](mailto:gilead.privacy@gilead.com).

BIKTARVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.